



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Todd C. Sacktor, et al.

Examiner: Unassigned

Serial No.: 10/533,595

Art Unit: Unassigned

Filed: May 2, 2005

Docket: 15878

For: ATYPICAL PROTEIN KINASE
C ISOFORMS IN DISORDERS OF THE
NERVOUS SYSTEM AND CANCER

Dated: June 16, 2005

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. Moscat J. et al., "The Atypical Protein Kinase Cs", *EMBO Reports*, 1(5):399-403 (2000);
2. Shao C.Y. et al., "Atypical Protein Kinase C (PKC) Colocalizes with Tau-and α-Synuclein-Related Inclusions in Neurodegenerative Disorders", *Society for Neuroscience Abstracts* 02-07 (2002), Abstract 592.9;

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Dated: June 16, 2005


Peter I. Bernstein

3. Shao C.Y. et al., "Association of PKC, P62 and Ubiquitin with Inclusions of Neurodegenerative Disease", *Society for Neuroscience Abstracts* 08-12 (2003), Abstract 203.22;
4. United States Patent Application Publication No. 2003/0068310 A1, published April 10, 2003 to Yin et al.; and
5. Hopf F.W. et al., "Atypical Protein Kinase C is a Novel Mediator of Dopamine-Enhanced Firing in Nucleus Accumbens Neurons", *The Journal of Neuroscience*, 25(4):985-989 (2005).


The references were cited in the International Search Report of a corresponding International PCT Application. Applicants are submitting copies of the above-cited reference nos. 1-3 and 5, together with a copy of the Search Report. In accordance with the waiver of 37 C.F.R. § 1.98 (a)(2)(i) in effect as of June 30, 2003, applicants are not required to submit a copy of the above-cited U.S. Patent Publication reference. The relevance of the above-identified references has been described in the Search Report.

The undersigned attorney hereby states that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

Respectfully submitted,

Peter I. Bernstein
Registration No. 43,497

Scully, Scott, Murphy & Presser
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343

PIB:dg

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80) PATENT AND TRADEMARK OFFICE		Atty. Docket No. (Optional)	Application Number				
LIST OF PRIOR ART CITED BY APPLICANT		15878	10/533,595				
(Use several sheets if necessary)							
		Applicant(s) Todd C. Sacktor, et al.					
		Filing Date May 2, 2005	Group Art Unit Unassigned				
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA						
	AB						
	AC						
U.S. PATENT APPLICATION PUBLICATIONS							
EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA	2003/0068310 A1	4/10/03	Yin et al.			
	AB						
FOREIGN PATENT DOCUMENTS							
REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
OTHER DOCUMENTS (<i>Including Author, Title, Date, Pertinent Pages, Etc.</i>)							
		Moscat J. et al., "The Atypical Protein Kinase Cs", <i>EMBO Reports</i> , 1(5):399-403 (2000)					
		Shao C.Y. et al., "Atypical Protein Kinase C (PKC) Colocalizes with Tau-and α -Synuclein-Related Inclusions in Neurodegenerative Disorders", <i>Society for Neuroscience Abstracts</i> 02-07 (2002), Abstract 592.9					
		Shao C.Y. et al., "Association of PKC, P62 and Ubiquitin with Inclusions of Neurodegenerative Disease", <i>Society for Neuroscience Abstracts</i> 08-12 (2003), Abstract 203.22					
		Hopf F.W. et al., "Atypical Protein Kinase C is a Novel Mediator of Dopamine-Enhanced Firing in Nucleus Accumbens Neurons", <i>The Journal of Neuroscience</i> , 25(4):985-989 (2005)					
EXAMINER			DATE CONSIDERED				
<p>* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
 15878

In Re Application Of: Todd C. Sacktor, et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/533,595	May 2, 2005	Unassigned	23389	Unassigned	Unassigned

Title:

**A TYPICAL PROTEIN KINASE C ISOFORMS IN DISORDERS OF THE NERVOUS SYSTEM
 AND CANCER**

Address to:

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Docket No.

15878

In Re Application: Todd Sacktor, et al.

JUN 20 2005

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/533,595	May 2, 2005	Unassigned	23389	Unassigned	Unassigned

Title:

**ATYPICAL PROTEIN KINASE C ISOFORMS IN DISORDERS OF THE NERVOUS SYSTEM
AND CANCER****Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of _____ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
- Charge the amount of _____
 - Credit any overpayment.
 - Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**Certificate of Transmission by Facsimile***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

June 16, 2005


(Date)

Signature of Person Mailing Correspondence

Peter I. Bernstein

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.



Signature

Dated: June 16, 2005

Peter I. Bernstein

Registration No. 43,497

Scully, Scott, Murphy & Presser
 400 Garden City Plaza, Suite 300
 Garden City, New York 11530
 516-742-4343

CC: